InterPharmaLink’s track record of Partnering arrangements, Mergers & Acquisitions, and strategic consultancy projects include:

Partnering

• Managed the sale of a Phase 2 dermatology compound to BIOFRONTERA (Germany) on behalf of ASAT (Switzerland)
• Managed the licensing-in of a Phase 2 acute cardiovascular compound from AETAS (Japan) on behalf of NOVACARDIA (USA)
• Managed the licensing-in of a Phase 2 oncology compound on behalf of a US specialty pharma company
• Partnering of a Phase 3 oncology project (RENIALE) on behalf of LIPONOVA (Germany)
• Search for oncology compounds for in-licensing on behalf of a US specialty pharma company
• Search for GI compounds for in-licensing on behalf of a US specialty pharma company
• Search for anti-infective compounds for in-licensing on behalf of an Asian specialty pharma company

Mergers & Acquisitions

• Managed the set-up of the European subsidiary and the transfer of global rights to a Phase 3 gynecology compound on behalf of SHOGOO (Japan)
• Advised acquisition process of a one billion euro pan-European pharma business on behalf of a globally active pharma company
• Advised acquisition process of a multi-billion euro international OTC business on behalf of a major European pharma company
• Advised acquisition process of a European OTC business on behalf of a major Japanese pharma company
• Advised the divestment of a pharmaceutical dosage form production facility in Singapore on behalf of WYETH (USA)
• Advised the divestment of five premium pharmaceutical dosage form production facilities in Europe, Latin America, and Asia on behalf of SCHERING (Germany)

Strategic consultancy

• Developed market entry and partnering strategy into Europe on behalf of a major Japanese pharma company
• Developed market entry and partnering strategy into Europe on behalf of an emerging pharma company in the Middle East
• Developed business strategy and transformation concept for a contract development and manufacturing company
• Developed a manufacturing and supply chain strategy for public US specialty pharma company